Takeda Pharmaceutical Reports Experimental Dengue Vaccine Safe, Effective In Late-Stage Trial

Reuters: Takeda dengue vaccine meets main goal of trial; detailed results to come
“Takeda Pharmaceutical Co. said on Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of the Japanese drugmaker’s late-stage clinical trial…” (Steenhuysen, 1/29).

Wall Street Journal: Takeda’s Dengue Vaccine Works Safely, Company Says
“…An estimated 390 million people are infected with the mosquito-borne dengue virus in tropical regions around the world each year. But only one licensed vaccine, Dengvaxia from Sanofi SA, has been available so far to offer protection, and it has safety problems. … Takeda said its vaccine, called TAK-003, protected children for at least one year against dengue infection caused by four different types of the virus in the late-stage trial. No safety problems were observed with the vaccine, Takeda said…” (Hopkins/McKay, 1/29).

Additional coverage of the experimental vaccine trial results is available from Bloomberg and Reuters.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.